Review
Copyright ©The Author(s) 2017.
World J Hepatol. Mar 8, 2017; 9(7): 352-367
Published online Mar 8, 2017. doi: 10.4254/wjh.v9.i7.352
Table 1 Main features of antiviral targets and clinical indications of second-generation direct acting antivirals[17]
MoleculeClassTargetGenotypeAssociations
SofosbuvirNucleotide polymerase inhibitorNS5B RNA-dependent RNA polymerasePangenotypicLedipasvir
Daclatasvir
Simeprevir
Velpatasvir
DasabuvirNon-nucleoside polymerase inhibitorNS5B RNA-dependent RNA polymeraseGenotype 1Ombitasvir + paritaprevir + ritonavir
OmbitasvirNS5AGenotype 1, 4Paritaprevir + ritonavir with or without dasabuvir
DaclatasvirNS5AGenotype 1, 2, 3Sofosbuvir
LedipasvirNS5AGenotype 1, 4Sofosbuvir
VelpatasvirNS5APangenotypicSofosbuvir
ElbasvirNS5AGenotype 1, 4Grazoprevir
ParitaprevirNS3/4A proteaseGenotype 1, 4Ombitasvir + ritonavir with or without dasabuvir
SimeprevirNS3/4A proteaseGenotype 1, 4Sofosbuvir
GrazoprevirNS3/4A proteaseGenotype 1, 4Elbasvir